home / stock / cgtx / cgtx quote
Last: | $2.37 |
---|---|
Change Percent: | -0.48% |
Open: | $2.11 |
Close: | $2.37 |
High: | $2.535 |
Low: | $2.1 |
Volume: | 2,486,959 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.37 | $2.11 | $2.37 | $2.535 | $2.1 | 2,486,959 | 07-26-2024 |
$2.1 | $1.82 | $2.1 | $2.14 | $1.8 | 536,837 | 07-25-2024 |
$1.84 | $1.81 | $1.84 | $1.84 | $1.77 | 112,286 | 07-24-2024 |
$1.79 | $1.9 | $1.79 | $1.9 | $1.709 | 408,393 | 07-23-2024 |
$1.88 | $1.88 | $1.88 | $1.92 | $1.8 | 186,372 | 07-22-2024 |
$1.84 | $1.98 | $1.84 | $1.98 | $1.805 | 154,847 | 07-19-2024 |
$1.94 | $1.93 | $1.94 | $1.98 | $1.92 | 57,241 | 07-18-2024 |
$1.92 | $2.05 | $1.92 | $2.05 | $1.89 | 111,796 | 07-17-2024 |
$1.98 | $1.94 | $1.98 | $2.01 | $1.89 | 62,342 | 07-16-2024 |
$1.92 | $2.01 | $1.92 | $2.09 | $1.9 | 89,901 | 07-15-2024 |
$1.98 | $1.87 | $1.98 | $1.99 | $1.85 | 72,450 | 07-12-2024 |
$1.83 | $1.88 | $1.83 | $1.92 | $1.83 | 95,021 | 07-11-2024 |
$1.86 | $2.07 | $1.86 | $2.0781 | $1.86 | 166,415 | 07-10-2024 |
$2.06 | $1.92 | $2.06 | $2.12 | $1.92 | 157,798 | 07-09-2024 |
$1.88 | $1.93 | $1.88 | $1.97 | $1.87 | 70,857 | 07-08-2024 |
$1.91 | $1.8 | $1.91 | $2 | $1.8 | 124,305 | 07-05-2024 |
$1.77 | $1.8 | $1.77 | $1.8893 | $1.75 | 88,536 | 07-04-2024 |
$1.77 | $1.8 | $1.77 | $1.8893 | $1.75 | 88,536 | 07-03-2024 |
$1.82 | $1.75 | $1.82 | $2.04 | $1.7297 | 660,397 | 07-02-2024 |
$1.67 | $1.68 | $1.67 | $1.7599 | $1.65 | 79,944 | 07-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Cognition Therapeutics Inc. Company Name:
CGTX Stock Symbol:
NASDAQ Market:
Cognition Therapeutics Inc. Website:
PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders will host an investor webcast on Monday, July 29, 2024...
PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts summarizing clinical e...
Completed enrollment for Phase 2 SEQUEL trial in mild-to-moderate Alzheimer’s disease (AD); topline results expected 2Q 2023 SHINE (AD) trial currently enrolling patients with first patient in Spain enrolled. Expect full enrollment by end of 2023 Received FDA clearance to...